Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2024.0390 ↗Kurz gefasst
Fallbericht in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Pushkar Aggarwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Keratoacanthoma, Skin Neoplasms, Carcinoma, Squamous Cell, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study assesses risk of dermatological immune-related adverse events associated with immunotherapy for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Zitieren
APA
Aggarwal, P., Clark, D., Shah, A., Rismiller, K., & Neltner, S. A. (2024). Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.0390
Vancouver
Aggarwal P, Clark D, Shah A, Rismiller K, Neltner SA. Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.0390
BibTeX
@article{Aggarwal2024,
author = {Aggarwal, Pushkar and Clark, Denise and Shah, Aatman and Rismiller, Kyle and Neltner, Scott A},
title = {Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2024.0390}
}
EUVIMED